Company news
Idorsia Ltd. (SIX:IDIA) news
Idorsia Ltd. news releases on 6ix. Latest, Jun 25, 2025: Bondholders approve amended terms of the 2025 and 2028 convertible bonds
Press releases — page 2
Bondholders approve amended terms of the 2025 and 2028 convertible bonds
June 25, 2025
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
June 25, 2025
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
June 23, 2025
Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia
June 10, 2025
Idorsia publishes invitations to bondholder meetings
June 6, 2025
Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025
May 28, 2025
New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability
May 21, 2025
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
May 2, 2025
Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset
April 30, 2025
New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine
April 29, 2025
Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond
April 16, 2025
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension
April 9, 2025
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement
April 9, 2025
Idorsia publishes its Annual Report 2024
March 27, 2025
US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients
March 17, 2025
Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia
March 14, 2025
Idorsia announces financial results for 2024
March 4, 2025
Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call
February 27, 2025
Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations
February 26, 2025
Idorsia and Viatris update their collaboration for selatogrel and cenerimod
February 26, 2025
Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties
February 26, 2025
Bondholders approve amended terms of the 2025 convertible bonds
February 25, 2025